Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT05822271
Recruiting Not applicable

Evaluation of Surgical Outcomes of Patients Treated With the Surgery First Approach and Aligners

NCT05822271 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2022-01-30
Last updated
2024-12-02

Condition(s) studied

Malocclusion, Angle Class III

Investigational drug(s) / intervention(s)

Orthognathic Surgery

Orthognathic Surgery: Type of surgery performed to correct skeletal malocclusions

Study summary

The purpose of this prospective study is to compare treatment outcomes and the quality of life of skeletal Class III patients treated with conventional fixed appliances and aligners undergoing Surgery-first approach. Data will be collected through validated questionnaires: OQLQ (Orthognathic Quality of Life Questionnaire), OHIP-14 (Oral Health Impact Profile), SF-36 (Medical Outcomes Study 36 - Item Short-Form Health Survey) and IOTN (Index of Orthodontic Treatment Need).

Eligibility

Sex
ALL
Min age
17 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adults; * Skeletal malocclusion; * ANB Angle zero or negative; * Witts negative; * Etiology: mandibular excess, a maxillary deficiency, or a combination of both; * Indication for bimaxillary surgery; Exclusion Criteria: * Previous orthodontic treatment; * Craniofacial anomaly or previous fracture of the facial bones; * Total edentulism; * Deep curve of Spee; * Vertical asymmetry; * Any medication use that contraindicates surgical treatment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Rio de Janeiro State University Rio de Janeiro Brazil Recruiting

More Rio de Janeiro State University trials in Brazil

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05822271 on ClinicalTrials.gov ↗ ← All trials in Brazil